ALFA Finder| Revenue growth | 40% YoY growth in FY26. |
|---|---|
| Margins | EBITDA margin at 20.3% (up 72 bps); PAT margin 14% (up 129 bps). |
| Demand visibility | Strong visibility for nutraceutical CDMO platform. |
| Management confidence | Strong; FY27 growth guidance of 25-30% provided. |
Growth
Revenue grew 40% YoY to ₹146.8 cr; EBITDA rose 45% to ₹29.9 cr; PAT surged 54% to ₹20.5 cr.
Outlook
FY27 growth guidance of 25-30%; ₹37 cr IPO-funded capex to increase capacity by 2.5x by H2FY27.
Risks
Decline in RoE from 37% to 20.4% and RoCE from 48.8% to 25.8% YoY.
Earnings Call filed with NSE, NSE: INFLUX. Summary written with AI assistance from the document.
Influx Healthtech Ltd: key numbers
- Share price
- ₹280.25
- Market cap
- ₹648.8 Cr
- Revenue (annual)
- ₹146.8 Cr
- Net profit (annual)
- ₹20.54 Cr
- P/E (TTM)
- 31.6×Sector 43.7×
- Promoter holding
- 73.53%
- FII holding
- 0.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Influx Healthtech Ltd
All →Influx Healthtech Earnings Call Transcript: Key Takeaways
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
- Call
- Guides 25% growth
Influx Healthtech Investor Presentation: Key Takeaways
H1 FY27 revenue ₹85.4cr (+27.9%), EBITDA ₹18.3cr (+25.1%, 21.5% margin), PAT ₹12.0cr (+20.0%). Capacity expansion and wellness launches drive growth.
- Call
- Guides 25% growth
Influx Healthtech H1 FY27 Results: Net Profit ₹12 Cr, Up 20.0% YoY
Influx Healthtech Ltd reported revenue from operations of ₹85.4 Cr (+27.8% YoY) and net profit of ₹12 Cr (+20.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹12 Cr · +20.0% YoY
Influx Healthtech Legal & Regulatory
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
- Value
- ₹0.02 Cr
Influx Healthtech Annual General Meeting
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech Other Announcement
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.